Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck

Head and Neck

Volumn 33, Issue 2, 2011, Pages 208-215

  Chikamatsu, Kazuaki ^a   Takahashi, Goro ^a   Sakakura, Koichi ^b   Ferrone, Soldano ^b   Masuyama, Keisuke ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

cancer stem cells; CD44; immunosuppression; squamous cell carcinoma of the head and neck; tumor immunity

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HERMES ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CELL TYPE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOREGULATION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNOLOGY;

ANTIGENS, CD44; BIOLOGICAL MARKERS; CARCINOMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HLA-A2 ANTIGEN; HUMANS; NEOPLASMS, SQUAMOUS CELL; NEOPLASTIC STEM CELLS;

EID: 78751553162     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21420     Document Type: Article

References (39)

1. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF,. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988. (Pubitemid 36418143)
3. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ,. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
4. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115.
5. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
6. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104: 973-978.
7. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE,. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007; 14: 3629-3637.
8. Kang MK, Kang SK,. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 2007; 16: 837-847.
9. Dylla SJ, Beviglia L, Park IK, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS ONE 2008; 3: e2428.
10. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
11. Whiteside TL,. Tricks tumors use to escape from immune control. Oral Oncol 2009; 45: e119-123.
12. Zou W,. Immunosuppressive networks in the tumour environment their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274.
13. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE,. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE 2008; 3: e3077.
14. Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL,. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 2007; 364: 778-782.
15. Okamoto A, Chikamatsu K, Sakakura K, Hatsushika K, Takahashi G, Masuyama K,. Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. Oral Oncol 2009; 45: 633-639.
16. Chikamatsu K, Sakakura K, Yamamoto T, Furuya N, Whiteside TL, Masuyama K,. CD4+ T helper responses in squamous cell carcinoma of the head and neck. Oral Oncol 2008; 44: 870-877.
17. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S,. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 2003; 62: 385-393.
18. Bandoh N, Ogino T, Cho HS, et al. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 2005; 66: 185-194.
19. Wang X, Campoli M, Cho HS, et al. A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods 2005; 299: 139-151.
20. Lampson LA, Fisher CA, Whelan JP,. Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 1983; 30: 2471-2478.
21. Ogino T, Wang X, Ferrone S,. Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J Immunol Methods 2003; 278: 33-44.
22. Fricke I, Mirza N, Dupont J, et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007; 13: 4840-4848.
23. Basak GW, Yasukawa S, Alfaro A, et al. Human embryonic stem cells hemangioblast express HLA-antigens. J Transl Med 2009; 7: 27.
24. Le Blanc K, Tammik C, Rosendahl K, Zetterg E, Ringden O,. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-896.
25. Cabrera CM, Nieto A, Cortes JL, et al. The low rate of HLA class I molecules on the human embryonic stem cell line HS293 is associated with the APM components' expression level. Cell Biol Int 2007; 31: 1072-1078.
26. Meissner M, Reichert TE, Kunkel M, et al. Defects in the human leukocyte antigen class I antigen-processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 2005; 11: 2552-2560.
27. Ogino T, Shigyo H, Ishii H, et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 2006; 66: 9281-9289.
28. Raffaghello L, Nozza P, Morandi F, et al. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Res 2007; 67: 5471-5478.
29. Han LY, Fletcher MS, Urbauer DL, et al. HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008; 14: 3372-3379.
30. Young MR, Wright MA, Lozano Y, Matthew JP, Benefield J, Prechel MM,. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 1996; 29: 333-338.
31. Waugh DJ, Wilson C,. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-6741.
32. Mroczko B, Szmitkowski M,. Hematopoietic cytokines as tumor markers. Clin Chem Lab Med 2004; 42: 1347-1354.
33. Massague J,. TGFβ in cancer. Cell 2008; 134: 215-230.
34. Mani SA, Guo W, Liao M-J, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
35. Morel A-P, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A,. Generation of breast cancer stem cells through epithelial-mesenchymal transition PLoS ONE 2008; 3: e2888.
36. Kabashima A, Higuchi H, Takaishi H, et al. Side population of pancreatic cancer cells predominates in TGF-β-mediated epithelial to mesenchymal transition and invasion. Int J Cancer 2009; 124: 2771-2779.
37. Frumento G, Piazza T, Di Carlo E, Ferrini S,. Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 2006; 6: 233-237.
38. Nagaraj S, Gabrilovich DI,. Myeloid-derived suppressor cells. Adv Exp Med Biol 2007; 601: 213-223.
39. Schatton T, Frank MH,. Antitumor immunity and cancer stem cells. Ann NY Acad Sci 2009; 1176: 154-169.